

6. Literatur

1. Scholze J. Hypertonie. Risikokonstellationen & Begleiterkrankungen. Praxisnahe Diagnostik und Individualtherapie. Blackwell Wissenschafts-Verlag, Berlin, 1999
2. Scholze J. Hypertonie kompakt. 2002; Blackwell Wissenschafts-Verlag, Berlin.
3. American Society of Consultant Pharmacists. Reducing cardiovascular risk in the long-term care setting: evaluating new management options. http://www.macmcm.com/ascp/ascp2001_01.htm.
4. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension. Can better care cost less? *J Am Med Assoc* 2004;291:1850-56.
5. Yosefy C, Ginsberg GM, Dicker D, et al. Risk factor profile and achievement of treatment goals among hypertensive patients from the Israeli Blood Pressure Control (IBPC) program - initial cost utility analysis. *Blood Pressure* 2003;12:225-31.
6. Jönsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. *J Intern Med* 2003;253:472-80.
7. He J, Muntner P, Chen J, et al. Factors associated with hypertension control in the general population of the United States. *Arch Intern Med* 2002;162:1051-58.
8. Hyman D, Pavlik V. Characteristics of patients with uncontrolled hypertension in the United States. *N Engl J Med* 2001;345:479-86.
9. Basle JN. Hypertension 2001: how will JNC VII be different from JNC VI? *South Med J* 2001;94: 889-90.
10. Joffres MR, Harnet P, MacLean DR, et al. Distribution of blood pressure and hypertension in Canada and the United States. *AmJHypertens* 2001;14:1099-05.
11. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. *J Am Med Assoc* 2003;290:199-206.
- 11a. Laurent S. Guidelines from the British Hypertension Society. *Br Med J* 2004;328:634-35.
12. Hansson L, Llyod A, Andersen P, Kopp Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. *Blood Pressure* 2002;11:35-45.
13. Andersen TW. Re-Examination of some of the Framingham blood-pressure data. *Lancet II* 1978;1139-41.
14. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med* 1993;153:598-615.
15. McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990;335:765-74.
16. ESH/ESC Hypertension Guidelines Committee. Practic guidelines for primary care physicians: 2003 ESH/ESC Hypertension Guidelines. *J Hypertens* 2003;21:1779-86.
17. Deutsche Liga zur Bekämpfung des hohen Blutdrucks e.V. Merkblatt: Empfehlungen zur Hochdruckbehandlung. 16. Aufl., November 2003.
18. JNC VII 2003: The Seventh Report of the Joint National Committee on Prevention , Detection, Evaluation, and Treatment of High Blood Pressure. *JAMA*;289:2560-

- 71
19. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *Br Med J* 2004;328:634-40.
 20. Singer GM, Izhar M, Black HR. Guidelines for hypertension: are quality-assurance measures on target? *Hypertension* 43;198-202.
 21. Hense HW. Epidemiologie der arteriellen Hypertonie und Implikationen für die Prävention. *Dtsch Med Wschr* 2000;125:1397-02.
 22. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
 23. Klein W. Zielblutdruckwerte aus kardiologischer Sicht. *Wien Med Wschr* 1999;149:625-28.
 24. Skrabal F. Eine kritische Analyse der Hypertension Optimal Treatment (HOT)-Studie (erschienen im *Lancet* 1998: 351: 1755-1762) *WienMed Wschr* 1999;149:621-24.
 25. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and acetylsalicylic acid in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998;351:1755-62.
 26. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? *J Hypertens* 2003;21:979-804.
 27. WHO World Health Organisation - International Society of Hypertension. Guidelines for the management of hypertension. *J Hypertension* 1999;17:151-83.
 28. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1997;157(21):2413-46.
 29. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA* 2003; 289:2363-9.
 30. Scholze J. Basic principles and possible variations in combination antihypertensive therapy. *Z Arztl Fortbild* 1997;91:155-63.
 31. Scholze J. Differentialtherapie mit Calciumantagonisten. *Herz* 2003;28:754-63.
 32. De Luca N, Rosiello G, Lamenza F. Reversal of cardiac and large artery structural abnormalities induced by long term antihypertensive treatment with trandolapril. *Am J Cardiol* 1992;70:52-59.
 33. Schartl M, Boksch WG, Dreysse S. Remodelling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients. *J Hypertens* 1994;12 (Suppl.4):37-42.
 34. van Bortel LM, Kool Boudier HAS. Effects of antihypertensive agents on local arterial distensibility and compliance. *Hypertension* 1995;26:531-34.
 35. Scholze J. Pulse Pressure in der Therapiesteuerung der Hypertonie? *Herz* 2004;29:276-89.
 36. Schiffrin EL, Deng LY. Comparison of effects of angiotensin converting enzyme inhibitors and beta blockade on function of small arteries from hypertensive patients. *Hypertension* 1995;25:699-703.
 37. Scholze J. Basic principles and possible variations in combination antihypertensive therapy. *Z Arztl Fortbild* 1997;91:155-63.

38. SOLVD (1991): Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 325:293-302.
39. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin –converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The Captopril Prevention Project (CAPPP) randomised trial. *Lancet* 1999;353:611-16
40. Pfeffer MA, Braunwald E, Meyé LA, et al. Effect of captopril on morbidity in patients left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial (SAVE). *N Engl J Med* 1992;327:669-77.
41. The Acute Invarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet* 1993;342:8218.
42. Kober L, Torp-Pedersen C, Carlsen JR, et al. A clinical trail of the antiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 1995;333:1670-76.
43. The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med* 2000;342:145-53.
44. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *2003 Dec 3;290(21):2805-16.*
45. Wright JT, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. *Arch Intern Med* 2002;162:1636-43.
46. Jacob SV, Scholze J, Wirth A. Hypertonietherapie beim metabolischen Syndrom. *Notfall & Hausarztmedizin* 2006;32:132-36.
47. Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. *ClinExp Hypertension* 1999;21:1447-62.
48. Scholze J, Pahl I, Rautenberg B, Thiel U. Antihypertensive Kombinationstherapie mit ACE-Hemmern. *Z Ärztl Fortbild* 1992;86:389-95.
49. Dahlof B, Sever PS, Poulter NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005;366(9489):895-906.
50. Mosby's Drug Consult. Ramipril: categories, drug classes, brand names & costs of therapy. (Accessed September 20, 2002, at http://www.mosbysdrugconsult.com/genrxfree/Top_200_2000/drugs/E3032.htm.)
51. Mosby's Drug Consult. Felodipine: categories, drug classes, brand names & costs of therapy. (Accessed September 20, 2002 at http://www.mosbysdrugconsult.com/genrxfree/Top_200_2000/drugs/E3059.htm.)
52. Deutsche Hochdruckliga e. V. DHL. Deutsche Hypertonie Gesellschaft. Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie. *Nieren- u. Hochdruckkrankheiten* 2005;34(11):481-98
53. Keil U. Neue Aspekte zur Epidemiologie der Hypertonie in Deutschland. *Ärztezeitung* 1992;135:5-9.
54. Brainbridge AD, Macfadyen RJ, Lees KR, et al. A study of the acute

- pharmacodynamic interaction of ramipril and felodipine in normotensive subjects. *Br J Clin Pharmacol*; 1991;31:148-53.
55. Black HR, Elliott WJ, Weber MA, et al. One-year study of felodipine of placebo for stage I isolated systolic hypertension. *Hypertension* 2001; 38:1118-23.
 56. Hansson L, Lindhohn LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardio-vascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999;354:1751-56.
 57. Herlitz H, Harris K, Risler T, et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros study. *Nephrol Dial Transplant* 2001;16:2158-65.
 58. Högglund C, Hutchinson HG. A comparison of nisoldipine coat-core and felodipine in the treatment of mild-to-moderate hypertension. *Int J Clin Pract* 1998;52:221-25.
 59. Kjeldsen SE, Hedner T, Jamerson K, et al. Hypertension Optimal Treatment (HOT) study. Home blood pressure in treated hypertensive subjects. *Hypertension* 1998;31:1014-20.
 60. Mayet J, Ariff B, Wasan B, et al. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. *Hypertension* 2000;34:755-59.
 61. Mayet J, Chapman N, Shahi M, et al. The effects of cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. *Am J Hypertens* 1997;10:611-18.
 62. Pedersen EB, Bech JN, Nielsen CB, et al. A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. *Scand J Clin Lab Invest* 1997;57:673-81.
 63. Reuter MK, Lorenz H, Verho P, et al. Effects of felodipine ER, a dihydropyridine calcium antagonist, on blood pressure and serum lipids. *Curr Med Res Opinion* 1998;14:97-103.
 64. Sawicki PT. Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimes. *Nephrol Dial Transplant* 1997;12:1890-99.
 65. Schaefer RM, Aldons PM, Burgess ED, et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. *Int J Clin Pract* 1998;52:381-86.
 66. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of Felodipine or Ramipril to long-term treatment with β -blockade. *Am J Hypertens* 1995;8:113-23.
 67. Verho M, Smith NA, Lorenz H, et al. Efficacy of ramipril in therapy-resistant hypertension. *Curr Med Res Opinion* 1998;14:117-25.
 68. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. *Am J Hypertens* 2004;17(10):904-10.
 69. Scholze J, Patschan S, Doerffel Y, et al. Therapy of obesity-associated hypertension. *Dtsch Med Wochenschr* 2005(130)46:2645-50.
 70. Wirth A zit. nach Scholze J. Hypertonie. Risikokonstellationen & Begleiterkrankungen. Praxisnahe Diagnostik und Individualtherapie. 1999; Blackwell Wissenschafts-Verlag.
 71. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US

- adults. Findings from the Third National Health and Nutrition Examination Survey. *J Am Med Assoc* 2002;287:356-59.
72. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. *Diabetologica* 2003;46:182-89.
 73. Wicklmayr M, Rett K, Standl E. How can primary prevention of coronary heart disease be improved in general practice? *Med Klin (Munich)* 1994(4):184-6,229.
 74. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;24(4):683-9.
 75. Hiepe F, Scholze J. Medikamentös bedingte Blutdruckregulationsstörungen. In: J. Scholze. *Hypertonie, Risikokonstellationen und Begleitkrankheiten*. Blackwell Verlag, Berlin-Wien 1999;522-28.
 76. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. *Ann Intern Med* 1994;121:289-300.
 77. Bluthochdruck und sympathisches Nervensystem: Einfluss der Herzfrequenz auf die Prognose. *Herz/Kreislauf* 1999;31(6):247-53.
 78. Palatini P, Julius S. Heart rate and the cardiovascular risk. *J Hypertens* 1997;15:3-17.
 79. Dyer AR, Stamler J, Shekelle RB, et al. Pulse pressure-I. Level and associated factors in four Chicago epidemiologic studies. *J Chron Dis* 1982;35:259-73.
 80. Persson H, Andreasson K, Kahan T, et al. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. *Eur J Heart Fail* 2002;4(1):73-82.
 81. Eriksson SV, Eneroth P, Kjekshus J, et al. Neuroendocrine activation in relation to left ventricular function in Cooperative North Scandinavian Enalapril Survival Study. (CONSENSUS). *Clin Cardiol* 1994;17(11):603-6.
 82. Scholze J. Sibutramine in clinical practice – a PMS-study with positive effects on blood pressure and metabolic parameters. *Dtsch Med Wochenschr* 2002;127(12):606-10.
 83. Poisson B, Bauer B, Schueler E, et al. Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. *Curr Med Res Opin* 1996;13(8):445-56.
 84. Mervaala EMA, Teräväinen TL, Malmberg L, et al. Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. *Br J Pharmacol* 1997;121:503-10.
 85. Coca A, Calvo C, Sobrino J, et al. Low-dose fixed combination therapy is a better strategy than dose increasing in patients not controlled by monotherapy: a double-blind, randomized study assessed by 24-h ambulatory blood pressure monitoring [abstract no. P2.173]. *J Hypertens* 2001 Jun;19 Suppl 2:152.
 86. Cvetkovic RS, Plosker GL. Ramipril/Felodipine extended-release fixed-dose combination. A review of its use in the management of essential hypertension. *Drugs* 2005;65(13):1851-68.
 87. Messerli FH. Combination in the treatment of hypertension: ACE inhibitors and calcium antagonists. *Am J Hypertens* 1999 Aug;12(8Pt 2 Suppl):86S-90S.
 88. Schmieder R. Reduction of left ventricular hypertrophy (LVH) by antihypertensive therapy: results of a meta-analysis of all double blind randomised studies. *J Am Coll Cardiol* 2001;37:261A-62A.
 89. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet* 2005 Mar 12;365(9463):939-46

90. Asmar RG. Pulse Pressure. An important tool in cardiovascular pharmacology. *Drugs* 2003;63:927-32.
91. Verdecchia P, Schillaci G, Reboldi G, et al. Different prognostic impact of 24-hour mean blood pressure on stroke and coronary artery disease in essential hypertension. *Circulation* 2001;103:2579-84.
92. London GM. Large artery function and alterations in hypertension. *J Hypertens* 1995;13:Suppl 2:35-8.
93. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. *Circulation* 2003;107:2864-9.
94. Greene AS, Tonellato PJ, Lui J, et al. Microvascular rarefaction and tissue vascular resistance in hypertension. *Am J Physiol* 1989;256:H126-31.
95. Levy BI, Ambrosio G, Pries AR, et al. Microcirculation in hypertension: a new target for treatment? *Circulation* 2001;104:735-40.
96. Franklin SS, Larson M, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. *Circulation* 2001;103:1245-9.
97. Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. *J Hypertens* 2002;20:145-51.
98. Karpanou E, Vyssoulis G, Daskalova D, et al. Differential effect of antihypertensive drugs on pulse pressure. *Eur Heart J* 2002;4:Suppl:208.abstract.
99. Schiffrin EL, Denk LY. Structure and function of resistance arteries of hypertensive patients treated with a b-blocker or calcium channel antagonist. *J Hypertens* 1996;14:1247-55.
100. Schiffrin EL, Pu Q, Park JB. Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. *Am J Hypertens* 2002;15:105-10.
101. Sihm I, Schroeder AP, Aalkjaer C, et al. Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. *Am J Hypertens* 1998;11:263-7.
102. Seideman P, Ekeröth M, Östman J. Effect of felodipine and refractory hypertension. *Drugs Exptl Clin Res* 1988;16:587-92.
103. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender. *Blood Pressure* 1995;4:313-19.
104. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. *Blood Pressure* 1997;6:313-17.
105. Hansson L. Recent Intervention trials in hypertension initiated in Sweden - HOT, CAPP and others. *Clin Exp Hypertension* 1999;21:507-15.
106. Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax®) and enalapril in the treatment of hypertension. *Clin Exp Hypertension* 1998;8:833-846.
107. Moser M. Current recommendations for the treatment of hypertension: are they still valid? *J Hypertens* 2002;20(Suppl.1):3-10.